Stabilized Z Domain Polypeptide Scaffold for Pharmaceutical Applications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Z variant polypeptides lack improved stability, which is crucial for pharmaceutical applications as it affects their functional longevity and shelf-life, both during production and within the human body.
Innovation Solution
Development of a novel polypeptide scaffold with specific amino acid sequences and methods for producing polypeptide variants that exhibit enhanced stability, affinity for predetermined targets, and improved properties such as alkali stability and reduced antigenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Z variant polypeptides are used for pharmaceutical applications, then binding affinity to targets can be achieved, but structural stability and shelf-life are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions within the Z domain scaffold. Multiple substitutions are introduced at positions including 3, 4, 10, 11, 16, 17, 18, 20, 21, 25, 26, 28, 29, 30, 32, 35, 36, 39, 45, 46, and 47 to optimize structural stability while preserving binding function.
Solution Approach 2:
The patent creates composite polypeptide structures by combining the stabilized Z domain scaffold with various functional domains including binding specificities for different targets, Fc regions for half-life extension, and albumin-binding domains. This composite approach allows simultaneous optimization of stability, binding affinity, and pharmacokinetic properties.
2Reliability
If Z variant polypeptides are used, then binding function can be provided, but alkali stability is insufficient
Solution Approach 1:
Specific amino acid substitutions are introduced to enhance resistance to chemical modifications and improve alkali stability. Key substitutions include introducing disulfide bonds through cysteine residues at strategic positions and modifying residues prone to chemical degradation.
3Object-affected harmful factors
If Z variant polypeptides are used, then binding affinity can be achieved, but antigenicity is reduced only partially
Solution Approach 1:
The patent reduces antigenicity through systematic amino acid substitutions that humanize the polypeptide sequence while maintaining structural integrity and binding function. Substitutions are made at positions likely to be recognized by the immune system, replacing non-human residues with human-equivalent amino acids.
Data Source
AI summary
The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55). The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q (SEQ ID NO: 55), and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.